Identification

Name
Fluphenazine
Accession Number
DB00623  (APRD00633)
Type
Small Molecule
Groups
Approved
Description

A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine. [PubChem]

Structure
Thumb
Synonyms
  • 1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine
  • 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine
  • 10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
  • 2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol
  • 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
  • 4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
  • 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol
  • 4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
  • Flufenazina
  • Fluorfenazine
  • Fluorophenazine
  • Fluorphenazine
  • Fluphenazin
  • Fluphénazine
  • Fluphenazinum
  • Triflumethazine
External IDs
SQ 10733 / Squibb 16144
Product Ingredients
IngredientUNIICASInChI Key
Fluphenazine decanoateFMU62K1L3C5002-47-1VIQCGTZFEYDQMR-UHFFFAOYSA-N
Fluphenazine dihydrochlorideZOU145W1XL146-56-5MBHNWCYEGXQEIT-UHFFFAOYSA-N
Fluphenazine enanthateQSB34YF0W92746-81-8LRWSFOSWNAQHHW-UHFFFAOYSA-N
Fluphenazine hydrochlorideNot AvailableNot AvailableNot applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Fluphenazine Tab 2.5mgTablet2.5 mgOralApotex Corporation1977-12-31Not applicableCanada
FluphenazineTablet1 mgOralAa Pharma Inc1977-12-31Not applicableCanada
FluphenazineTablet2 mgOralAa Pharma Inc1977-12-31Not applicableCanada
FluphenazineTablet5 mgOralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazine 1 Tab 1mgTablet1 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 2 Tab 2mgTablet2 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 5 Tab 5mgTablet5 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine Decanoate Injection B.P.Liquid100 mgIntramuscular; SubcutaneousHospira, Inc.Not applicableNot applicableCanada
Fluphenazine Decanoate Injection B.P.Liquid25 mgIntramuscular; SubcutaneousHospira, Inc.Not applicableNot applicableCanada
Fluphenazine Decanoate Injection, USPSolution25 mgIntramuscular; SubcutaneousMylan PharmaceuticalsNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluphenazine InjectableLiquid25 mgIntramuscular; SubcutaneousApotex Corporation2001-10-052013-08-02Canada
Fluphenazine DecanoateInjection, solution25 mg/mLIntramuscular; SubcutaneousPar Pharmaceutical2014-07-09Not applicableUs
Fluphenazine DecanoateInjection25 mg/mLIntramuscular; SubcutaneousWest Ward Pharmaceutical1996-08-30Not applicableUs
Fluphenazine DecanoateInjection, solution25 mg/mLIntramuscular; SubcutaneousTYA Pharmaceuticals2010-12-15Not applicableUs
Fluphenazine DecanoateInjection, solution25 mg/mLIntramuscular; SubcutaneousFresenius Kabi2010-12-15Not applicableUs
Fluphenazine DecanoateInjection, solution125 mg/5mLIntramuscular; SubcutaneousAuro Medics Pharma Llc2017-10-17Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralClinical Solutions Wholsesale1988-08-122017-06-20Us
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralAvera Mc Kennan Hospital2016-07-15Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralClinical Solutions Wholsesale1987-10-162017-06-24Us
Fluphenazine hydrochlorideTablet, film coated2.5 mg/1OralMylan Pharmaceuticals1988-08-12Not applicableUs
International/Other Brands
Anatensol (Bristol-Myers Squibb) / Dapotum D / Fludecasin (Tanabe Mitsubishi Pharma) / Fludecate (Rafa) / Flumezin (Tanabe Mitsubishi Pharma) / Funazine (Johnson) / Lyogen (Lundbeck) / Lyogen Depot (Lundbeck) / Lyogen Retard (Lundbeck) / Metoten (Hemofarm) / Modecate (Bristol-Myers Squibb) / Moditen (Bristol-Myers Squibb) / Moditen Depo (Krka) / Permitil / Prolixin (Bristol-Myers Squibb)
Categories
UNII
S79426A41Z
CAS number
69-23-8
Weight
Average: 437.522
Monoisotopic: 437.174867774
Chemical Formula
C22H26F3N3OS
InChI Key
PLDUPXSUYLZYBN-UHFFFAOYSA-N
InChI
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
IUPAC Name
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1

Pharmacology

Indication

For management of manifestations of psychotic disorders.

Structured Indications
Pharmacodynamics

Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.

Mechanism of action

Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
UCalmodulin
inhibitor
Human
UAndrogen receptorNot AvailableHuman
U5-hydroxytryptamine receptor 2ANot AvailableHuman
U5-hydroxytryptamine receptor 2CNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineFluphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineFluphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineFluphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFluphenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Fluphenazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Fluphenazine can be increased when it is combined with Abiraterone.Approved
AcebutololFluphenazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluphenazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluphenazine.Approved, Illicit, Investigational
AlprenololFluphenazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmiodaroneThe metabolism of Fluphenazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideFluphenazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Fluphenazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amperozide.Experimental
AmphetamineFluphenazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aripiprazole.Approved, Investigational
ArotinololFluphenazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
ArtemetherThe serum concentration of Fluphenazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Fluphenazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Fluphenazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Fluphenazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Fluphenazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Asenapine.Approved
AtenololFluphenazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Fluphenazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Fluphenazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Azaperone.Investigational, Vet Approved
AzelastineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital.Illicit
BefunololFluphenazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzocaine.Approved
BenzphetamineFluphenazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Fluphenazine can be decreased when combined with Betaxolol.Approved
BevantololFluphenazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideFluphenazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololFluphenazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololFluphenazine may increase the hypotensive activities of Bopindolol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluphenazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluphenazine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromperidol.Investigational
BrotizolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololFluphenazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolFluphenazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluphenazine.Approved, Investigational
BupranololFluphenazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Fluphenazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluphenazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluphenazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butacaine.Vet Approved
ButambenThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluphenazine.Approved, Illicit, Vet Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluphenazine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarteololFluphenazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolFluphenazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Fluphenazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololFluphenazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
Chloral hydrateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluphenazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Fluphenazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphentermineFluphenazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Fluphenazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineThe metabolism of Fluphenazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholecalciferolThe metabolism of Fluphenazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Fluphenazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Fluphenazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluphenazine.Approved, Vet Approved
CitalopramThe metabolism of Fluphenazine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Fluphenazine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Fluphenazine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Fluphenazine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clopenthixol.Experimental
CloranololFluphenazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Fluphenazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Fluphenazine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Fluphenazine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Fluphenazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluphenazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluphenazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclobenzaprine.Approved
Cycloguanil embonateThe serum concentration of Fluphenazine can be increased when it is combined with Cycloguanil embonate.Experimental
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluphenazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluphenazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Fluphenazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Fluphenazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Fluphenazine can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Fluphenazine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desflurane.Approved
DesipramineThe metabolism of Fluphenazine can be decreased when combined with Desipramine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineFluphenazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Diazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Diethyl ether.Experimental
DiethylpropionFluphenazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydromorphine.Experimental, Illicit
DiphenhydramineThe metabolism of Fluphenazine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Fluphenazine can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluphenazine.Approved, Investigational
DoxycyclineThe serum concentration of Fluphenazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fluphenazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Illicit
DronedaroneThe metabolism of Fluphenazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Fluphenazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluphenazine.Approved
EliglustatThe metabolism of Fluphenazine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluphenazine.Approved, Investigational, Vet Approved
EpanololFluphenazine may increase the hypotensive activities of Epanolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.Approved, Investigational
EsmololFluphenazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluphenazine.Approved
EthanolFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluphenazine.Approved, Illicit, Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluphenazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluphenazine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluphenazine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fludiazepam.Approved, Illicit
FlunitrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Fluphenazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flupentixol.Approved, Withdrawn
FlurazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe metabolism of Fluphenazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineFluphenazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Glutethimide.Approved, Illicit
HalazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Fluphenazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe metabolism of Fluphenazine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Hexobarbital.Approved
HydrocodoneFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluphenazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineFluphenazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Fluphenazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
ImipramineThe metabolism of Fluphenazine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Indalpine.Investigational, Withdrawn
IndenololFluphenazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Fluphenazine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Indiplon.Investigational
Iofetamine I-123Fluphenazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Fluphenazine can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Fluphenazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolFluphenazine may increase the hypotensive activities of Labetalol.Approved
LandiololFluphenazine may increase the hypotensive activities of Landiolol.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluphenazine.Approved
LevobunololFluphenazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levobupivacaine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluphenazine.Approved, Vet Approved
LisdexamfetamineFluphenazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Fluphenazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Fluphenazine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Loprazolam.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluphenazine.Approved
LorcaserinThe metabolism of Fluphenazine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluphenazine.Approved
LumefantrineThe serum concentration of Fluphenazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Fluphenazine can be decreased when combined with Manidipine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mebicar.Experimental
MedazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Fluphenazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Melperone.Approved, Investigational
MephedroneFluphenazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineFluphenazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololFluphenazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Meptazinol.Experimental
MequitazineFluphenazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mesoridazine.Approved, Investigational
MethadoneThe metabolism of Fluphenazine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineFluphenazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methaqualone.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluphenazine.Approved
MethotrimeprazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineFluphenazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethylecgonineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenobarbital.Approved
MetipranololFluphenazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluphenazine.Approved, Investigational
MetyrosineFluphenazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Midazolam.Approved, Illicit
MidomafetamineFluphenazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Fluphenazine can be decreased when combined with Midostaurin.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Investigational
MirabegronThe metabolism of Fluphenazine can be decreased when combined with Mirabegron.Approved
MirtazapineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Fluphenazine can be increased when it is combined with Mizoribine.Investigational
MMDAFluphenazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluphenazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Investigational
NadololFluphenazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluphenazine.Approved
NebivololFluphenazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nefazodone.Approved, Withdrawn
NevirapineThe metabolism of Fluphenazine can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Fluphenazine can be decreased when combined with Nicardipine.Approved
NicomorphineFluphenazine may increase the hypotensive activities of Nicomorphine.Experimental
NilotinibThe metabolism of Fluphenazine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Normethadone.Approved, Illicit
OlanzapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olanzapine.Approved, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Opium.Approved, Illicit
OrphenadrineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluphenazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Fluphenazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Fluphenazine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluphenazine.Approved
Peginterferon alfa-2bThe serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololFluphenazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluphenazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluphenazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenoxyethanol.Approved
PhentermineFluphenazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PimozideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pimozide.Approved
PindololFluphenazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipamperone.Approved, Investigational
PiperaquineThe serum concentration of Fluphenazine can be increased when it is combined with Piperaquine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Piritramide.Investigational
Platelet Activating FactorFluphenazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PractololFluphenazine may increase the hypotensive activities of Practolol.Approved
PramipexoleFluphenazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Fluphenazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prilocaine.Approved
PrimaquineThe serum concentration of Fluphenazine can be increased when it is combined with Primaquine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.Approved, Vet Approved
ProguanilThe serum concentration of Fluphenazine can be increased when it is combined with Proguanil.Approved
PromazineThe metabolism of Fluphenazine can be decreased when combined with Promazine.Approved, Vet Approved
PropanididThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propoxycaine.Approved
PropranololFluphenazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProxibarbalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluphenazine.Approved
PSD502The risk or severity of adverse effects can be increased when Fluphenazine is combined with PSD502.Investigational
PseudoephedrineFluphenazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Fluphenazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Fluphenazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Fluphenazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine.Approved
QuinidineThe metabolism of Fluphenazine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Fluphenazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Fluphenazine can be increased when it is combined with Radicicol.Experimental
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluphenazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluphenazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluphenazine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluphenazine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ritanserin.Investigational
RitobegronFluphenazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Fluphenazine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Fluphenazine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Romifidine.Vet Approved
RopiniroleFluphenazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluphenazine.Approved
RotigotineFluphenazine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Fluphenazine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluphenazine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluphenazine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Fluphenazine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluphenazine.Approved
SinefunginThe serum concentration of Fluphenazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
SotalolFluphenazine may increase the hypotensive activities of Sotalol.Approved
StiripentolThe metabolism of Fluphenazine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Fluphenazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Fluphenazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideFluphenazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sultopride.Experimental
SuvorexantFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TafenoquineThe serum concentration of Fluphenazine can be increased when it is combined with Tafenoquine.Investigational
TalinololFluphenazine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluphenazine.Approved
TerbinafineThe metabolism of Fluphenazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TertatololFluphenazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluphenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetrodotoxin.Investigational
ThalidomideFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluphenazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Fluphenazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tilidine.Experimental
TimololFluphenazine may increase the hypotensive activities of Timolol.Approved
TipranavirThe metabolism of Fluphenazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluphenazine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluphenazine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluphenazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Fluphenazine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluphenazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Fluphenazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TromethamineTromethamine can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluphenazine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluphenazine.Approved
VenlafaxineThe metabolism of Fluphenazine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Veralipride.Experimental
VilazodoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vilazodone.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Fluphenazine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zaleplon.Approved, Illicit, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Fluphenazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zolazepam.Vet Approved
ZolpidemFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Ullyot, G.E.; U.S. Patent 3,058,979; October 16, 1962; assigned to Smith Kline & French Laboratories.

US3058979
General References
Not Available
External Links
Human Metabolome Database
HMDB14761
KEGG Compound
C07010
PubChem Compound
3372
PubChem Substance
46506645
ChemSpider
3255
BindingDB
78433
ChEBI
5123
ChEMBL
CHEMBL726
Therapeutic Targets Database
DCL000806
PharmGKB
PA449676
IUPHAR
204
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluphenazine
ATC Codes
N05AB02 — Fluphenazine
AHFS Codes
  • 28:16.08.24 — Phenothiazines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Unknown StatusTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedDiagnosticPathological Gambling1
2CompletedTreatmentPsoriasis1
2TerminatedTreatmentPsoriasis1
3CompletedTreatmentSchizophrenic Disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • Bristol myers squibb co
  • Apothecon inc div bristol myers squibb
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Lannett holdings inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2.5 mg
LiquidIntramuscular; Subcutaneous25 mg
TabletOral1 mg
TabletOral2 mg
InjectionIntramuscular; Subcutaneous25 mg/mL
Injection, solutionIntramuscular; Subcutaneous125 mg/5mL
Injection, solutionIntramuscular; Subcutaneous25 mg/mL
ElixirOral.5 mg/mL
Injection, solutionIntramuscular2.5 mg/mL
Solution, concentrateOral5 mg/mL
TabletOral1 mg/1
TabletOral2.5 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral5 mg/1
LiquidIntramuscular; Subcutaneous100 mg
LiquidIntramuscular25 mg
TabletOral10 mg
TabletOral5 mg
ElixirOral.5 mg
SolutionIntramuscular; Subcutaneous25 mg
SolutionIntramuscular; Subcutaneous100 mg
Prices
Unit descriptionCostUnit
Fluphenazine Omega 100 mg/ml31.2USD ml
Modecate Concentrate 100 mg/ml31.2USD ml
Pms-Fluphenazine Decanoate 100 mg/ml31.2USD ml
Fluphenazine Decanoate 25 mg/ml Solution14.0USD ml
Fluphenazine 2.5 mg/ml vial7.82USD ml
Fluphenazine Omega 25 mg/ml5.22USD ml
Prolixin 10 mg tablet3.1USD tablet
Prolixin 5 mg tablet2.38USD tablet
Fluphenazine dec 25 mg/ml vial1.92USD ml
Prolixin 2.5 mg tablet1.63USD tablet
Fluphenazine 10 mg tablet1.25USD tablet
Fluphenazine HCl 10 mg tablet1.19USD tablet
Fluphenazine 5 mg tablet0.97USD tablet
Fluphenazine HCl 5 mg tablet0.94USD tablet
Fluphenazine 2.5 mg tablet0.84USD tablet
Fluphenazine HCl 2.5 mg tablet0.79USD tablet
Fluphenazine 1 mg tablet0.55USD tablet
Fluphenazine HCl 1 mg tablet0.52USD tablet
Apo-Fluphenazine 2 mg Tablet0.24USD tablet
Apo-Fluphenazine 1 mg Tablet0.18USD tablet
Apo-Fluphenazine 5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)224-226 (Salt)U.S. Patent 3,058,979
boiling point (°C)268-274 °C at 5.00E-01 mm HgPhysProp
water solubility31.1 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.36HANSCH,C ET AL. (1995)
logS-4.15ADME Research, USCD
pKa7.9EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.019 mg/mLALOGPS
logP4.4ALOGPS
logP3.97ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.27 m3·mol-1ChemAxon
Polarizability44.92 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9837
Blood Brain Barrier+0.975
Caco-2 permeable-0.5387
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.923
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.7669
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7091
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.937
CYP450 3A4 inhibitorNon-inhibitor0.715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7056
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8828
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8990 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9146
hERG inhibition (predictor II)Inhibitor0.8157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.44 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0bu4-9430100000-8ccf208ff236ff33462c
Mass Spectrum (Electron Ionization)MSsplash10-001i-2391100000-6928faa0b341426b2c11
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0310900000-a2a4be9e30f6506c9359
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0190000000-cf20413d597a3759305d

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / N-alkylpiperazines / Benzenoids / 1,4-thiazines / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols / Organopnictogen compounds
show 3 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / N-alkylpiperazine / Para-thiazine / 1,4-diazinane / Benzenoid / Piperazine
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, organofluorine compound, N-alkylpiperazine (CHEBI:5123)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  2. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395-402. [PubMed:7508675]
  3. Qin ZH, Weiss B: Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur J Pharmacol. 1994 Sep 15;269(1):25-33. [PubMed:7828655]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Van Kampen JM, Stoessl AJ: Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. Neuroscience. 2000;101(3):629-35. [PubMed:11113312]
  3. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405]
  4. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Mongin AA, Cai Z, Kimelberg HK: Volume-dependent taurine release from cultured astrocytes requires permissive [Ca(2+)](i) and calmodulin. Am J Physiol. 1999 Oct;277(4 Pt 1):C823-32. [PubMed:10516112]
  2. Kawai M, Nakashima A, Ueno M, Ushimaru T, Aiba K, Doi H, Uritani M: Fission yeast tor1 functions in response to various stresses including nitrogen starvation, high osmolarity, and high temperature. Curr Genet. 2001 May;39(3):166-74. [PubMed:11409178]
  3. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848]
  4. Nakabayashi H, Komada H, Yoshida T, Takanari H, Izutsu K: Lymphocyte calmodulin and its participation in the stimulation of T lymphocytes by mitogenic lectins. Biol Cell. 1992;75(1):55-9. [PubMed:1515867]
  5. Kauss H: Sensing of volume changes by poterioochromonas involves a ca-regulated system which controls activation of isofloridoside-phosphate synthase. Plant Physiol. 1981 Aug;68(2):420-4. [PubMed:16661928]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. Epub 2007 Jul 2. [PubMed:17606915]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. Epub 2007 Jul 2. [PubMed:17606915]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. Epub 2007 Jul 2. [PubMed:17606915]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]

Drug created on June 13, 2005 07:24 / Updated on January 14, 2018 10:04